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Abstract
Craniopharyngiomas are benign slow growing tumours that are located within the sellar and para
sellar region of the central nervous system. The point prevalence of this tumour is approximately
2/100,000. The onset of symptoms is normally insidious with most patients at diagnosis having
neurological (headaches, visual disturbances) and endocrine (growth retardation, delayed puberty)
dysfunctions. Craniopharyngiomas are thought to arise from epithelial remnants of the
craniopharyngeal duct or Rathke's pouch (adamantinomatous type) or from metaplasia of
squamous epithelial cell rests that are remnants of the part of the stomadeum that contributed to
the buccal mucosa (squamous papillary type). The neuroradiological diagnosis is mainly based on
the three components of the tumour (cystic, solid and calcified) in the characteristic sellar/para
sellar location. Definitive diagnosis is made following histological examination of a surgical
specimen. The differential diagnosis includes other tumours in this region (pituitary adenoma),
infectious or inflammatory processes (eosinophilic granuloma), vascular malformations (aneurysm)
and congenital anomalies (Rathke's cleft cyst). The current treatment is gross total excision of the
tumour, if there is no hypothalamic invasion or, in the presence of hypothalamic invasion, a sub-
total resection with post-operative radiotherapy. Endocrine disturbances are normally permanent
and need careful replacement. Overall, there is an 80% 5 year survival, though this can be associated
with marked morbidity (hypothalamic dysfunction, altered neuropsychological profile).
Disease name
Craniopharyngioma
Synonyms
Rathke's pouch tumour, craniopharyngeal duct tumour,
adamantinoma, adamantinomatous tumour, dysodon-
togenic epithelial tumour.
Definition and diagnostic criteria
The first description of a craniopharyngioma was in 1857
by Zenker. The term craniopharyngioma was introduced
in 1932 by Cushing and has been used widely thereafter.
In the International Classification of Diseases for Oncol-
ogy 3rd revision (ICD-O-3) the code number 9350 refers
to "unspecified craniopharyngioma", whilst 9351 and
9352 correspond to the two histological subtypes, ada-
mantinous and papillary craniopharyngiomas, respec-
tively.
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The diagnosis of a patient with a craniopharyngioma is
based on clinical (neurological and endocrine symptoms)
and radiological (a calcified solid/cystic mass) findings,
and is then confirmed by characteristic histological find-
ings.
Epidemiology
The incidence of newly diagnosed craniopharyngiomas
ranges from 0.13 to 2 per 100,000 population per year,
with a point prevalence of 1 to 3 per 100,000 population
[1-3]. There is no variance by gender or race. Distribution
by age is bimodal with the peak incidence in children at
5–14 years and in adults at 65–74 years of age. In chil-
dren, craniopharyngiomas account for 5% of all tumours
and 50% of all sellar/para sellar tumours [1,3].
Clinical description
Craniopharyngiomas are generally slow growing
tumours. Symptoms develop insidiously and there is
often a delay of 1–2 years between symptom onset and
diagnosis. The usual symptoms on presentation are [4,5]:
Raised intracranial pressure
headaches, nausea and vomiting either from mass effect
from the tumour itself or from secondary hydrocephalus
caused by obstruction of the foramen of Monro, the third
ventricle or the aqueduct of Sylvius
Endocrine dysfunction
normally suppressed endocrine function, for example
hypothyroidism, orthostatic hypotension, short stature,
diabetes insipidus, impotence and amenorrhoea, but
there can be an exaggeration of endocrine function, for
example precocious puberty in children and obesity in
adults.
Visual disturbance
classically a bitemporal hemianopia from inferior chias-
matic compression but alternatively patients may have a
homonymous hemianopia, scotoma and optic atrophy
with papilloedema.
Other presenting symptoms include chemical meningitis
(from rupture of cyst contents into the subarachnoid
space), seizures, poor school performance in children or
emotional lability and apathy in adults.
Aetiology
There are two histological phenotypes seen in craniophar-
yngioma: i) the adamantinomatous tumours, seen in chil-
dren, that resemble enamel forming neoplasm's in the
oropharynx and ii) the squamous papillary form, pre-
dominantly seen in adults. The characteristic location of
these tumours in the sellar and para-sellar region, together
with the different histological subtypes, allows for two
theories that may explain the origin of these tumours [6]:
The embryogenetic theory
this suggests that the adamantinomatous type arises from
epithelial remnants of the craniopharyngeal duct or
Rathke's pouch. The duct and pouch were derived from
the stomadeum, which, amongst other things, forms teeth
primordia.
The metaplastic theory
this suggests that the squamous papillary type occurs as a
result of metaplasia of squamous epithelial cell rests that
are remnants of the part of the stomadeum that contrib-
uted to the buccal mucosa.
Diagnostic methods
The diagnosis of a patient with a craniopharyngioma is
based on clinical and radiological findings and is then
confirmed by characteristic histological findings. The
evaluation of a patient with a probable craniopharyngi-
oma consists of [4]:
Imaging
The classical appearance of a craniopharyngioma is of a
sellar/para sellar part solid, part cystic calcified mass
lesion. These tumours occur in the supra sellar (75%),
supra and infra sellar (20%) and infra sellar (5%) regions
[7]. The supra sellar tumours may be subdivided into fur-
ther groups depending on their relationship to the third
ventricle and the optic chiasm [8]. The calcification is best
delineated on computerised tomography (CT) (Figure 1).
Magnetic resonance imaging (MRI) with and without con-
trast will, however, more accurately delineate the extent of
the tumour and, in particular, its involvement with the
hypothalamus (Figure 2). It is the investigation of choice
to plan the surgical approach. Magnetic resonance angiog-
raphy (MRA) is useful to not only delineate the course of
the vessels, which can be through the tumour, but also to
help differentiate a tumour from a possible vascular mal-
formation [7].
Endocrine assessment
The hypothalamic-pituitary axis hormones, namely
growth hormone, thyroid hormone, luteinising and folli-
cle stimulating hormone should be measured together
with cortisol levels and an assessment of serum and urine
osmolality. In addition, an estimate of bone age and, for
young females, ovarian ultrasonography is useful. Ideally,
any abnormalities should be corrected pre-operatively
but, at the very least, low cortisol levels and diabetes insip-
idus should be treated prior to a surgical procedure [9].Orphanet Journal of Rare Diseases 2007, 2:18 http://www.OJRD.com/content/2/1/18
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CT of a craniopharyngioma Figure 1
CT of a craniopharyngioma. This unenhanced CT shows a calcified cystic structure in the supra sellar region, together with 
hydrocephalusOrphanet Journal of Rare Diseases 2007, 2:18 http://www.OJRD.com/content/2/1/18
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Enhanced T1 weighted MRI's of craniopharyngiomas Figure 2
Enhanced T1 weighted MRI's of craniopharyngiomas. a. Apredominantly solid sellar/supra sellar tumour that is discrete 
fromthe hypothalamus (grade 0). b. A predominantly cystic sellar/suprasellar tumour that is distorting but not invading the 
hypothalamus (grade 1). c. A predominantly solid sellar/supra sellar tumour. The hypothalamus is not visible because of tumour 
invasion (grade 2).Orphanet Journal of Rare Diseases 2007, 2:18 http://www.OJRD.com/content/2/1/18
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Ophthalmology assessment
Visual acuity and visual field assessment is required to
delineate any deficit (e.g. field defects, central scotoma).
In addition, visualisation of the optic discs, to exclude
papilloedema, and visual evoked potentials should be
performed.
Histology
The tumour cells are small and have an epithelial appear-
ance. Numerous micro cystic spaces are formed. Addi-
tional findings include hyalinised calcified structures,
collagen, fibroblasts, foreign body giant cells and occa-
sionally cholesterol clefts.
Differential diagnosis
The differential diagnosis may be considered under four
main headings [4]:
Congenital anomalies
Arachnoid cyst and Rathke's cleft cyst.
Other Tumours
Pituitary tumour, metastasis, meningioma, epidermoid
and dermoid tumour, hypothalamic-optic pathway gli-
oma, hypothalamic hamartoma, teratoma.
Infectious/Inflammatory processes
Eosinophilic granuloma, lymphocytic hypophysitis, sar-
coidosis, syphilis and tuberculosis.
Vascular malformations
Aneurysm of the internal carotid or anterior communicat-
ing artery, arterio-venous malformation.
Genetic counselling
There is currently no known genetic relationship. There
are, however, a few familial cases reported in the literature
[10-12].
Management and treatment
The management of patients presenting with these unu-
sual tumours should ideally be in a specialised centre that
has a particular interest in them. The clinical presentation
of patients may be as an emergency with symptoms of
raised intracranial pressure or rapid deterioration in visual
function. Initial surgical treatment, for hydrocephalus or
tumour cyst decompression, to relieve these symptoms
and prevent further visual deterioration may be necessary,
prior to definitive treatment of the tumour.
There are two main management pathways with regards
to the treatment of the tumour. The first involves
attempted gross total resection of the tumour [8,13-18],
the second approach is for more limited surgery, aimed at
debulking the tumour to reduce the mass effect on the
optic pathways and/or to re-establish the cerebrospinal
fluid (csf) pathways, followed by radiotherapy [19-24].
The second pathway was developed because of the high
morbidity experienced with the gross total resection of
tumours that invade the hypothalamus [25-27]. The mor-
bidity can be considered in terms of hypothalamic dys-
function and an altered neuropsychological profile [28-
33].
In an attempt to balance the advantages of an aggressive
surgical resection against the risk of significant morbidity
associated with this, a pre-operative grading system has
recently been proposed that considers the extent of inva-
sion of the hypothalamus by the tumour as opposed to
the traditional anatomical localisation [34]. In this grad-
ing, type 0 represents no hypothalamic involvement, in
type 1 the tumour distorts or elevates the hypothalamus,
but the latter is still visible, whilst in type 2 tumours the
hypothalamus is no longer visible (Figure 2). In a cohort
of 66 paediatric patients there was a significant relation-
ship between a higher the pre-operative grade and a
higher rate of post-operative morbidity. Consequently, it
was proposed that a gross total resection should be
attempted in type 0 and 1 tumours and a sub-total resec-
tion, leaving only the hypothalamic component of the
tumour, in patients with a type 2 tumour [34]. It should
be noted, however, that the gross total removal of a
tumour that is not invading the hypothalamus or a sub-
total resection leaving only the hypothalamic component
of the tumour, is not without its risks. Furthermore, surgi-
cal experience has been noted to have a significant impact,
justifying the management of these patients in a centre
that has a particular interest in them [34]. Whilst this
grading system was developed in a paediatric population,
it could equally be applied to an adult population. There
is some evidence, however, that the craniopharyngiomas
that arise in adults are less likely to invade the hypothala-
mus. Nevertheless, in recent large adult series only about
50% of patients are having a gross total resection, which
is similar to paediatric series, because of the recognised
significant morbidity associated with surgical injury to the
hypothalamus [17,35].
Residual tumour, confirmed on post-operative MRI, is
generally treated with external beam radiotherapy, how-
ever, stereotactic radiosurgery (gamma knife) has been
used [36]. The use of proton beam radiotherapy for resid-
ual disease is currently being investigated [36].
Occasionally, a patient presents with a purely cystic
tumour. The management options for these tumours also
includes the stereotactic placement of a catheter to allow
repeated aspiration. Furthermore, the use of intracystic
radiotherapy (Yttrium-90 or Phosporus-32) [37] or chem-
otherapy (Bleomycin) [38] has had some success.Orphanet Journal of Rare Diseases 2007, 2:18 http://www.OJRD.com/content/2/1/18
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There is no place for systemic chemotherapy, however
recently the use of immunological therapy has been con-
sidered. Interferon alpha had a minimal effect when given
systemically but there has been some success when used
intracystically [39].
Post-operatively there is usually an improvement in visual
deficits [22]. Lifelong follow-up by an ophthalmologist is
however recommended. By contrast, the endocrine distur-
bances are likely to be permanent, if not exacerbated by
surgery [40]. Obesity is present in 50% of patients, whilst
about 80% of patients require two or more anterior pitui-
tary hormone replacement therapy and permanent diabe-
tes insipidus occurs in up to 75% of adults and 90% of
children [30]. Lifelong review by an endocrinologist is
clearly necessary.
Prognosis and quality of life
The overall five-year survival is 80% but the survival is bet-
ter in children (85% 5 year survival) than in older adults
(40% 5 year survival) [3,16,17]. Survival, however, may
be associated with marked disability.
The historical treatment of patients with craniopharyngi-
omas has been described as a pendulum [41]. The gross
total removal of a tumour that is invading the hypothala-
mus is technically demanding but achievable. There is,
however, a definite mortality (up to 10%) with this proce-
dure and despite a gross total resection a recurrence rate
(up to 15%) [5,8]. The clinical outcome however can be
less than ideal with hypothalamic dysfunction (hyper-
phagia, obesity, behavioural disorders, memory prob-
lems, loss of neurovegetative homeostasis) and an altered
neuropsychological profile (marked distractibility, diffi-
culties in perceptual organisation, poor verbal memory),
that even with the use of hormonal replacement therapy,
have a significant impact on daily activities in both adult
and paediatric patients [28,29,33,42]. The pendulum has
thus swung away from attempting gross total resection in
those patients with hypothalamic invasion to a less radi-
cal approach. In these patients, the hypothalamic compo-
nent of the tumour is left and treated with post-operative
radiotherapy. There is some recent evidence in a paediat-
ric population that the 5-year survival in patients with this
dichotomised regime is 80%, in keeping with previously
published series in which all the patients underwent a
gross total resection [34]. Whilst there is no improvement
in mortality using this treatment protocol, there is some
evidence that there is reduced hypothalamic dysfunction
in this population.
Unresolved questions
It is generally recommended that radiotherapy is given
following sub-total excision of a craniopharyngioma,.
This will reduce the likelihood of growth of the residual
tumour. There are, however, possible long-term complica-
tions with radiotherapy (cataracts, exacerbation of
hypothalamic-pituitary dysfunction, cognitive dysfunc-
tion, radionecrosis) [21,43]. In a recently published series,
20% of patients with a sub-total resection remained stable
during follow-up without radiotherapy [34]. It is currently
unclear as to whether all patients with residual tumour
should receive immediate post-operative radiotherapy.
There is evidence that surgical experience has an impact
on the clinical outcome of patients with a craniopharyn-
gioma. The sub-total removal of a tumour that is invading
the hypothalamus is not straightforward and yet it can be
speculated that the smaller the residual component the
greater the efficacy of the post-operative radiotherapy.
Despite the use of radiotherapy for residual disease, in
approximately 20% of patients the disease will recur
[21,34]. The only option in these patients is for aggressive
tumour removal. The long-term clinical outcome of these
patients is currently unknown.
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